Abstract
Introduction
Gram-negative bacilli belonging to the Enterobacteriaceae family are members of the normal colonic microbiota and these agents can be involved in virtually any type of human infections including urinary tract, bloodstream, intraabdominal, musculoskeletal, device-associated infections, pneumonia, meningitis, in both community and hospital settings (1, 2) .
Carbapenems are considered the most reliably active treatment option against severe infections caused by multidrug-resistant and extensively drug-resistant Gram-negative bacilli (2) (3) (4) . In Enterobacteriaceae, carbapenem resistance develops via two main mechanisms: (i) acquisition of carbapenemase genes that encode enzymes capable of degrading carbapenems, or (ii) overexpression of β-lactamases that possess very weak affinity for carbapenems coupled with modifications in permeability of porins and/or expression of efflux pumps (1) .
The worldwide emergence and spread of CP-CRE strains are an important growing public health concern due to very limited treatment options of infections caused by them (2) (3) (4) (5) . Carbapenemase genes are usually encoded on large transferable plasmids and are associated with various mobile genetic structures (insertion sequences, integrons, transposons), further enhancing their spread (1) . CP-CRE isolates are often resistant to all β-lactam drugs and frequently carry additional mechanisms conferring resistance to other antimicrobial classes (2) .
The most clinically important carbapenemases encountered in Enterobacteriaceae are categorized according to the Ambler classification system as follows: (i) class A serine β-lactamases (Klebsiella pneumoniae carbapenemases KPC), (ii) class B metallo-β-lactamases (New Delhi metallo-β-lactamase NDM, Verona integron-encoded metallo-β-lactamase VIM, Imipenemase IMP), and (iii) class D oxacillinases (OXA-48-like and its variants) (1, 2, 6) .
KPC enzymes emerged in North Carolina USA in 1996 and now are found worldwide, the principal reservoirs of bla NDM genes are the Indian subcontinent, the Balkan states and the Middle East and the OXA-48 type enzymes circulating among Mediterranean countries and being progressively disseminated to other geographical areas (1, 5) .
Recently, the World Health Organization (WHO) included CRE among pathogens with critical priority for research and development of new antibiotics (7) . Therefore, highly sensitive and specific methods for CP-CRE detection in clinical laboratory settings are critical (2, 4, 8) .
A limited number of published studies from our country about the geographical distribution, spread and type of carbapenemases are available (9) (10) (11) (12) (13) .
The aim of this study was to investigate phenotypic and genotypic characteristics of CP-CRE strains isolated from patients admitted to our hospital. In 2015, we diagnosed phenotypically our first 3 CP-CRE strains. In this paper, we report our first CP-CRE isolates that were molecularly confirmed.
Material and methods

Study design
We conducted a retrospective study between 1 st of January -1 st of July 2017 in the Department of Microbiology of "Dr. Constantin Opriș" County Emergency Hospital Baia Mare, Romania, which is a 920-bedded non-teaching hospital with surgical, orthopaedic, medical, haemato-oncological, paediatric and intensive care services. During the study period 1110 strains of Enterobacteriaceae were isolated from bronchial secretions, urine, wounds and blood cultures.
Bacterial strains and antimicrobial susceptibility testing Bacterial identification to the species level was performed by conventional methods including Vitek 2 Compact (bioMérieux, France) and API 20E (bioMérieux, France). Antibiotic susceptibility tests were done using disk-diffusion method, Vitek 2 Compact and M.I.C.E. strips with meropenem (Oxoid, UK). The minimal inhibitory concentration (MIC) to tigecycline was determined using Vitek AST-XN05 cards. The results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) 2017 criteria (14) .
Phenotypic detection of resistance mechanisms
In all Enterobacteriaceae strains non-susceptible to carbapenems, we performed the modified Hodge test (MHT) and the modified carbapenem inactivation method (mCIM) (14) . The combination disks test (KPC, MBL, OXA-48 Confirm kit, Rosco Diagnostica) was used for phenotypic confirmation of carbapenem-hydrolizing enzymes according to the manufacturer's instructions. Extended-spectrum β-lactamases (ESBLs) production was signaled by the automated system Vitek and was also evaluated by CLSI screening and confirmatory test methods (14) .
Molecular analysis of carbapenemase genes
Isolates stored at -70°C were subcultured and DNA was extracted from bacteria grown in 24h culture on solid medium. Multiplex PCR assays for carbapenemase encoding genes (bla KPC , bla NDM and bla OXA-48-like ) was carried out as described elsewhere (9) .
Results
CP-CRE strains
During the study period, we identified 43 carbapenem non-susceptible Enterobacteriaceae isolates from which only 19 non-duplicate strains recovered from 16 patients were phenotypically confirmed as CP-CRE as follows: Klebsiella pneumoniae (n=14; 73.68%), Escherichia coli (n=2; 10.52%), Providencia stuartii (n=2; 10.52%) and Serratia marcescens (n=1; 5.26%). Fourteen strains out of a total of 155 K. pneumoniae isolates were CP-CRE (9.03%). Of the remaining 24 carbapenem non-susceptible Enterobacteriaceae strains, more than half (n=16, 66.66%) were Enterobacter spp.
The CP-CRE strains were collected from bronchial secretions (n=9; 47.36%), urine (n=4; 21.05%), wounds (n=4; 21.05%) and blood cultures (n=2; 10.52%). These strains were isolated from patients hospitalized in the intensive care unit (ICU) (n=12; 63.15%), medical wards (n=5, 26.31%) and surgical units (n=2, 10.52%).
Phenotypic and molecular CP-CRE detection methods
MHT was positive in 15 of 19 CP-CRE strains with both meropenem and ertapenem disks ( Figure 1A ). The mCIM was positive in all 19 CP-CRE strains and no false-positive results were noticed ( Figure 1B) .
The carbapenem-hydrolizing enzymes were identified by the combination disks test (Rosco Diagnostica) as follows: KPC (n=9, 47.36%), OXA-48-like (n=5, 26.31%) and MBL (n=5, 26.31%). All five OXA-48-like isolates coproduced ESBL.
Carbapenemase-encoding genes were confirmed by multiplex PCR analysis in 18 available isolates with 100% agreement with the mCIM and combination disks test. The five MBL strains harbored bla NDM genes. No multiple carbapenemase genes in the same strain were identified.
Isolation of multiple CP-CRE strains from individual patients admitted to the intensive care unit (ICU)
In two patients from the same room, one of them previously hospitalized in another hospital from other Romanian geographical region, we isolated K. pneumoniae KPC and P. stuartii NDM from bronchial secretions. In one patient we detected E. coli OXA-48-like+ESBL and K. pneumoniae OXA-48-like+ESBL simultaneously from wound. In the other patient with congenital neuromusculare disease, we isolated successively K. pneumoniae OXA-48-like+ESBL from urine, wound and bronchial secretions.
Antimicrobial susceptibility profiles by carbapenemase gene Among our CP-CRE strains 100% were resistant to ertapenem, 94.73% to imipenem and 89.47% to meropenem (Table 1) . Only 4 OXA-48-like+ESBL isolates displayed a meropenem MIC≤8 mg/L and the rest of CP-CRE strains exhibited high level resistance (MIC≥16 mg/L) ( Figure 2 ).
Our investigation revealed that all 9 KPC-positive strains were resistant to aminopenicillins, to third and fourth-generation cephalosporins, to fluoroquinolones, aztreonam, sulfonamides, and gentamicin displayed in vitro activity against 7 of these strains.
NDM-positive strains presented resistance to almost all classes of antibiotics and fewer strains were resistant to amikacin, gentamicin, aztreonam, nitrofurantoin and colistin.
The OXA-48-like+ESBL strains were resistant to third and fourth-generation cephalosporines, piperacillin-tazobactam, aztreonam and exhibited susceptibility to amikacin, tigecycline and colistin.
Three (1 KPC and 2 OXA-48-like+ESBL) out of 9 K. pneumoniae strains tested against colistin were found resistant (MIC≥16 mg/L). Of 9 K. pneumoniae isolates tested against tigecycline we noted 1 KPC strain resistant (MIC≥8 mg/L).
Discussions
In recent years, we have witnessed the emergence and worldwide dissemination of the CP-CRE strains (1, 2, 5, 6, 15) . Both clonal spread and plasmid-mediated transmission contribute to the ongoing rise in incidence of these bacteria (1, 2, 15) . The emergence and spread of CP-CRE were found to be related to different factors: antimicrobial use exerts ecological pressure on bacteria, poor infection control measures, cross-border transfer of patients, travel, medical tourism and international migration (6) . The most common CP-CRE species isolated in our study were K. pneumoniae. In 2013, the US Centers for Disease Control and Prevention (CDC) reported similar distribution (16) . Also, the resistance situation for K. pneumoniae remains problematic, especially in countries in the Southern and Eastern parts of Europe (17) . In 2016, the proportion of invasive carbapenem resistant K. pneumoniae isolates reported to the European Antimicrobial Resistance Surveillance Network EARS-Net varied from <1% in some of the Nordic countries to 25-50% in Italy, Romania, and more than 50% in Greece (17) . Data from EARS-Net showed a correlation between national antimicrobial consumption levels and resistance to the same antimicrobial groups in K. pneumoniae (6) . In our study, carbapenemases were responsible for carbapenem resistance in 19 isolates (44.18%). The remaining 55.81% strains were most likely with reduced carbapenem susceptibility due to a dual resistance mechanisms: a cephalosporinase or ESBLs associated with porin mutations, loss of porin expression or efflux mechanism (1, 3).
Our study highlights that the majority of CP-CRE strains harboured gene bla KPC . The epidemiology of CRE varies by continent, country, region, and even center-to-center levels (2, 15) . Of all carbapenemase families encountered in Enterobacteriacea, KPC carbapenemases have the most extensive global distribution (15) . In the United States KPC is the predominant carbapenemase and KPC-producers are unevenly distributed among the U.S. states (2, 15) . KPC are also widespread in South and Central America, while Europe Italy and Greece reported an endemic occurence of KPC in 2014-2015 (15) . KPC enzymes have also been found in Israel, China, Tanzania and South Africa (15) .
Previous studies conducted in different Romanian geographical areas suggested that OXA-48-like and NDM were the main prevalent carbapenemases detected, while KPC enzymes were identified only sporadically (3, (9) (10) (11) (12) (13) . In Europe NDM producers are most commonly found in Romania, Poland and Denmark, where "inter-regional spread" (epidemiological stage 4) is deemed to be present (18) .
To our knowledge, this is the first Romanian report, where KPC was the main carbapenemase detected. Notably, we remarked the first occurrence in our hospital of P. stuartii harbouring gene bla NDM . K. pneumoniae and E. coli isolates are the most commonly mentioned NDM-producers (5), nevertheless an increasing number of Enterobacteriaceae genera including C. freundii, M. morganii, E. cloacae, K. oxytoca have been found carrying bla NDM, as a consequence to its particularly highly mobile encoding conjugative plasmid which facilitate horizontal interand intraspecies transfer between bacteria rather than clonal spread (19) . Phenotypic detection of CP-CRE is complicated by the fact that the level of carbapenem resistance induced by the expression of carbapenemases is heterogeneous (5, 6) and there is no single phenotypic or genotypic test being suitable for all situations (2, 20) . Detection of carbapenemases in isolates based only on MIC values has low sensitivity and specificity (20) .
MHT is simple and inexpensive to perform and has already demonstrated great ability to detect KPC producers, as well as VIM, IMP, and OXA-48-like enzymes (2). In our study, MHT was positive for all KPC and OXA-48-like isolates tested using both meropenem and ertapenem disks.
Also, our results revealed 2 strains of P. stuartii, 1 strain of S. marcescens and 1 isolate of K. pneumoniae harbouring gene bla NDM , which were negative for the MHT with both meropenem and ertapenem disks. Similar reports recognized the MHT unsatisfying performance in the detection of NDM-carriers, with sensitivity below 50% (2, 8, 14, 21, 22) . Recent studies demonstrated that NDM is a lipoprotein anchored to the outer membrane in Gram-negative bacteria, unlike all other known carbapenemases (21) . Pasteran et al. demonstrated that false negative results with MHT appear in NDM variants with this cellular localization and proposed a simple improvement of MHT, called the Triton Hodge Test (THT), by addition of a nonionic surfactant during the test (21) . Also, Sun et al. reported an improvement in detection sensitivity of NDM-producers from 65.2% with MHT to 91.3% with the THT (22) .
A newer phenotypic method for detection of carbapenemase activity is the mCIM (14) . Several studies demonstrated high sensitivity of mCIM for CP-CRE screening (2, 4, 8) . The mCIM is an affordable assay using familiar materials and methods and the test can be interpreted objectively (8) . Our findings with mCIM and the combination disks test were in accordance with multiplex PCR results. Molecular techniques remain the gold standard for precise identification of carbapenemase genes (23) .
The CLSI and the European Committee on Antimicrobial Susceptibility Testing EUCAST have recommended reporting of susceptibility in accordance with the antimicrobial susceptibility test result (5, 8, 14) . Detection of carbapenemase activity is undeniably important for epidemiological and infection control purposes and many would argue that it would be beneficial when making treatment decisions (8, 20) .
In our findings, consistent with previous reports (3, 5, 6, 12, 20, 24) , only few antibiotics remained effective against some of our CP-CRE strains: gentamicin, colistin, tigecycline. We observed 7 KPC-producing strains susceptible or intermediate susceptible to gentamicin and simultaneously resistant to amikacin. Ko et al. showed that gentamicin was not an adequate treatment option for amikacin-resistant K. pneumoniae, when the antibiotic susceptibility tests were performed by Vitek 2. The same authors experienced gentamicin treatment failure in K. pneumoniae bacteraemia that was susceptible to gentamicin despite amikacin resistance, as determined by Vitek 2. The false gentamicin susceptibility was associated with the armA 16S rRNA methylase gene (25) .
Current clinical evidence for treatment guidance is limited and based on retrospective observational studies and case reports (5, 20) . Combination regimens including colistin, carbapenems, tigecycline, aminoglycosides and fosfomycin have been used (5, 20) . Many CP-CRE isolates may present with discrete elevations of MICs for carbapenems and these drugs were used as potential treatment options in high-dose regimens (5, 20) . Unfortunately, in most of our tested strains high level resistance was noted to meropenem (MIC≥16 mg/L), which compromises the possibility of synergistic action of using meropenem in an antibiotic combination scheme (3). Daikos et al. found that patients treated for carbapenemase-producing K. pneumoniae bacteraemia with a carbapenem MIC≤8 mg/L in combination with other active agents had a lower mortality than those with a MIC˃8 mg/L (19.3% versus 35.5%) (24) .
With the emergence of resistance to colistin and tigecycline, some of the few remaining treatment alternatives for patients infected with CP-CRE, represent a major concern (18, 26) . We noted 3 strains of K. pneumoniae resistant to colistin recovered from bronchial secretion and wounds. Also, we observed 1 KPC-producing strain from bloodstream infection resistant to tigecycline (CMI≥8 mg/L). Polymyxin resistance, which is usually chromosomally mediated leading to modification of lipid A, was recently found to occur through acquisition of a plasmid-mediated gene, mcr1 (26) . In EARSNet report for 2016, Greece and Romania reported a combined resistance to carbapenems and colistin between 10-25% (17). However, as routine colistin susceptibility testing has several methodological issues, the extent of the problem is difficult to assess based on EARS-Net data (17) . Recently, Chiu et al. demonstrated that tigecycline resistance may occur without previous exposure to tigecycline and resistance mechanisms to tigecycline are not limited to increased expression of efflux pump genes such as acrB and/or oqxB (27) .
Avoidance of inappropriate antimicrobial use and comprehensive infection prevention and control strategies targeting all healthcare sectors are the key measures of effective interventions aiming to prevent selection and transmission of bacteria resistant to antimicrobial agents (17) .
Limitations of the study
Epidemiological and clinical data were not collected. Detection of cephalosporinase overexpression, porin mutations and efflux mechanism were not confirmed by laboratory analysis.
Conclusions
We have described the emergence of CP-CRE strains in a non-teaching Romanian hospital located in the North of the country. Although these have been reported from many large Romanian university hospitals since 2012, their presence in non-teaching hospitals is not very well known, but their spread is to be expected via patient transfers between hospitals. Awareness of this phenomenon, rapid and reliable detection of CP-CRE is critical for preventing their further spread in these settings.
